Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features - PubMed (original) (raw)
Clinical Trial
. 2008 Sep 1;26(25):4063-71.
doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4.
Robert Gray, Sunil Badve, Barrett H Childs, Carl Yoshizawa, Steve Rowley, Steven Shak, Frederick L Baehner, Peter M Ravdin, Nancy E Davidson, George W Sledge Jr, Edith A Perez, Lawrence N Shulman, Silvana Martino, Joseph A Sparano
Affiliations
- PMID: 18678838
- PMCID: PMC2654377
- DOI: 10.1200/JCO.2007.14.4501
Clinical Trial
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
Lori J Goldstein et al. J Clin Oncol. 2008.
Erratum in
- J Clin Oncol. 2009 Jul 20;27(21):3566
Abstract
Purpose: Adjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features.
Patients and methods: A sample of 465 patients with hormone receptor (HR) -positive breast cancer with zero to three positive axillary nodes who did (n = 99) or did not have recurrence after chemohormonal therapy had tumor tissue evaluated using a 21-gene assay. Histologic grade and HR expression were evaluated locally and in a central laboratory.
Results: Recurrence Score (RS) was a highly significant predictor of recurrence, including node-negative and node-positive disease (P < .001 for both) and when adjusted for other clinical variables. RS also predicted recurrence more accurately than clinical variables when integrated by an algorithm modeled after Adjuvant! that was adjusted to 5-year outcomes. The 5-year recurrence rate was only 5% or less for the estimated 46% of patients who have a low RS (< 18).
Conclusion: The 21-gene assay was a more accurate predictor of relapse than standard clinical features for individual patients with HR-positive operable breast cancer treated with chemohormonal therapy and provides information that is complementary to features typically used in anatomic staging, such as tumor size and lymph node involvement. The 21-gene assay may be used to select low-risk patients for abbreviated chemotherapy regimens similar to those used in our study or high-risk patients for more aggressive regimens or clinical trials evaluating novel treatments.
Trial registration: ClinicalTrials.gov NCT00003519.
Figures
Fig 1.
(A) Five-year recurrence rates by Recurrence Score (RS) as a categoric variable by nodal status. RS risk categories: low risk is RS less than 18; intermediate risk is RS 18 to 30; high risk is RS ≥ 31. Relationship between RS and recurrence as a continuous variable for (B) all patients with hormone receptor (HR) –positive disease and (C) HR-positive and human epidermal growth factor receptor 2 (HER-2) –negative disease where HER-2–positive disease was excluded. The rug plots above the x-axis show the individual patients with recurrence in black and the individual patients without recurrence in green. The large CIs at higher RS reflect the relatively small number of patients with RS greater than 50. Pts, patients.
Fig 2.
Five-year recurrence probabilities predicted by the integrator using local and central grade. For cases with the same result for local and central grade, the two values are equal (so the points are on the diagonal). Points above the diagonal have a higher risk grade category for central than for local and patients below the diagonal have a higher risk grade category for local than for central.
Fig 3.
Recurrence score risk percentiles compared with the integrator risk percentiles calculated using (A) local grade (correlation coefficient = 0.10) or (B) central grade (correlation coefficient = 0.19).
Fig 4.
Area under the receiver operating characteristic curves (AUC) for (A) Recurrence Score (RS), (B) the integrator using local grade, and (C) the integrator using central grade.
Fig 5.
(A) Relative risk of recurrence by Recurrence Score (RS) within subsets defined by the integrator predicted risk level. The area of the box is inversely proportional to the variance of the log hazard ratio, and the line indicates the CI. (B) Relative risk of recurrence by integrator risk group within subsets defined by RS risk groups. The area of the box is inversely proportional to the variance of the log hazard ratio, and the line indicates the CI. (C) Absolute 5-year risk of recurrence (and 95% CIs) by RS risk group within subsets defined by integrator-predicted risk level. Intermed, intermediate. Absolute 5-year risk of recurrence (and 95% CIs) by RS risk group within subsets defined by integrator predicted risk level.
Comment in
- An ideal prognostic test for estrogen receptor-positive breast cancer?
Paik S, Tang G, Fumagalli D. Paik S, et al. J Clin Oncol. 2008 Sep 1;26(25):4058-9. doi: 10.1200/JCO.2008.16.7528. Epub 2008 Aug 4. J Clin Oncol. 2008. PMID: 18678837 No abstract available. - Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer.
Roukos DH. Roukos DH. J Clin Oncol. 2009 Mar 10;27(8):1337-8; author reply 1338-9. doi: 10.1200/JCO.2008.20.2812. Epub 2009 Feb 2. J Clin Oncol. 2009. PMID: 19188673 No abstract available.
Similar articles
- Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
Lu K, Li H, Wu Z, Liu D, Ye H, Xu L, Liu Y. Lu K, et al. J BUON. 2018 Sep-Oct;23(5):1297-1301. J BUON. 2018. PMID: 30570850 - Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V. Henry NL, et al. J Clin Oncol. 2019 Aug 1;37(22):1965-1977. doi: 10.1200/JCO.19.00948. Epub 2019 Jun 17. J Clin Oncol. 2019. PMID: 31206315 - Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review. - Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G, Wen HY. Turashvili G, et al. Breast J. 2020 Jun;26(6):1199-1207. doi: 10.1111/tbj.13859. Epub 2020 May 26. Breast J. 2020. PMID: 32458521 Review.
Cited by
- Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Wang J, et al. Breast Cancer Res Treat. 2024 Jan;203(1):73-83. doi: 10.1007/s10549-023-07119-3. Epub 2023 Sep 26. Breast Cancer Res Treat. 2024. PMID: 37751078 - Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer.
Li J, Yao J, Qi L. Li J, et al. Mol Biotechnol. 2024 Sep;66(9):2467-2480. doi: 10.1007/s12033-023-00880-2. Epub 2023 Sep 24. Mol Biotechnol. 2024. PMID: 37742297 - The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer.
Chen K, Wu J, Fang Z, Shao X, Wang X. Chen K, et al. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221117402. doi: 10.1177/15330338221117402. Technol Cancer Res Treat. 2022. PMID: 36976899 Free PMC article. Review. - The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing.
Turner BM, Finkelman BS, Hicks DG, Numbereye N, Moisini I, Dhakal A, Skinner K, Sanders MAG, Wang X, Shayne M, Schiffhauer L, Katerji H, Zhang H. Turner BM, et al. Cancers (Basel). 2023 Jan 31;15(3):903. doi: 10.3390/cancers15030903. Cancers (Basel). 2023. PMID: 36765860 Free PMC article. - Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K, Yao L, Zhu J, Gu X, Wang J, Qian W, Zheng Z, Fu D, Wu S. Shen K, et al. BMC Cancer. 2022 Aug 8;22(1):863. doi: 10.1186/s12885-022-09952-z. BMC Cancer. 2022. PMID: 35941565 Free PMC article.
References
- Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005 - PubMed
- Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 - PubMed
- Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005 - PubMed
- Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA32291/CA/NCI NIH HHS/United States
- CA66636/CA/NCI NIH HHS/United States
- CA25224/CA/NCI NIH HHS/United States
- CA21115/CA/NCI NIH HHS/United States
- CA23318/CA/NCI NIH HHS/United States
- CA32012/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical